Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
12/16/2011
Trade Name:
Maxalt and Maxalt-MLT
Generic or Proper Name (*):
rizatriptan
Indications Studied:
Treatment of migraine
Therapeutic Category:
Antimigraine
Ages Studied:
6 - 17 years
Study #:
1
Study Type:
Safety/Pharmacokinetic/Tolerability
Study Design:
Open Label
No Patients:
31
BPCA(B), PREA(P):
B
Unknown:
0
-
-